Hanseatic Management Services Inc. Acquires 5,856 Shares of Illumina, Inc. $ILMN

Hanseatic Management Services Inc. acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 5,856 shares of the life sciences company’s stock, valued at approximately $1,603,000. Illumina comprises 1.0% of Hanseatic Management Services Inc.’s portfolio, making the stock its 28th largest holding.

Other hedge funds and other institutional investors have also made changes to their positions in the company. VestGen Advisors LLC bought a new position in Illumina during the 3rd quarter valued at about $392,000. Laurel Wealth Advisors LLC bought a new stake in Illumina in the third quarter worth about $55,000. Ashton Thomas Securities LLC lifted its stake in Illumina by 3.3% in the third quarter. Ashton Thomas Securities LLC now owns 1,348 shares of the life sciences company’s stock worth $369,000 after purchasing an additional 43 shares during the last quarter. Verdence Capital Advisors LLC purchased a new position in shares of Illumina during the third quarter valued at approximately $990,000. Finally, Leo Wealth LLC purchased a new position in shares of Illumina during the third quarter valued at approximately $1,981,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

ILMN has been the topic of a number of analyst reports. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $215.00 target price on shares of Illumina in a research note on Friday, July 31st. Citigroup boosted their price objective on Illumina from $95.00 to $113.00 and gave the company a “sell” rating in a report on Monday, August 3rd. Guggenheim upped their price objective on Illumina from $226.00 to $305.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. UBS Group upgraded Illumina from a “neutral” rating to a “buy” rating and increased their target price for the stock from $135.00 to $260.00 in a research note on Wednesday, September 9th. Finally, TD Cowen lifted their target price on Illumina from $210.00 to $270.00 and gave the stock a “hold” rating in a research report on Tuesday, October 13th. Ten analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $234.41.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Earnings anticipation supported the stock. Investors are looking for another revenue and adjusted-EPS beat after Illumina exceeded expectations in the second quarter and raised its full-year outlook. Analysts are likely to focus on NovaSeq X demand, clinical sequencing adoption, margins, and updated 2026 guidance. Why Illumina (ILMN) Stock Is Up Today
• Positive Sentiment: Recent operating momentum has improved investor sentiment. The company previously reported year-over-year revenue growth, stronger-than-expected results, and rising demand for its sequencing platforms and clinical applications. Several institutions also increased their Illumina holdings in recent filings, including FMR, PRIMECAP, Wellington, and Ninety One. What to expect from Illumina’s Q3 earnings
• Neutral Sentiment: The upcoming investor conference provides another potential catalyst. Illumina management is scheduled to participate in the Jefferies Global Healthcare Conference on November 17, giving investors an opportunity to hear additional commentary on demand, strategy, and the outlook. Illumina To Webcast Upcoming Investor Conference
• Negative Sentiment: Insider selling and valuation remain risks. Quiver reported 108 open-market insider sales and no purchases over the past six months, including substantial selling by Keith Meister. In addition, the reported median analyst price target of $185 is well below recent trading levels, suggesting limited near-term upside if earnings or guidance disappoint. Why Illumina (ILMN) Stock Is Up Today

Illumina Price Performance

Shares of ILMN stock opened at $288.79 on Thursday. The company has a market capitalization of $43.61 billion, a P/E ratio of 53.88, a P/E/G ratio of 3.82 and a beta of 1.41. The company’s 50-day simple moving average is $247.14 and its two-hundred day simple moving average is $174.99. Illumina, Inc. has a one year low of $94.00 and a one year high of $309.35. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%. The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the previous year, the business earned $1.19 earnings per share. Illumina’s quarterly revenue was up 9.4% on a year-over-year basis. As a group, equities analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current year.

Insiders Place Their Bets

In other Illumina news, SVP Christensen Wedel sold 1,033 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the sale, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. This represents a 6.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith Meister sold 119,501 shares of the firm’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $218.40, for a total value of $26,099,018.40. Following the transaction, the director owned 770,350 shares in the company, valued at approximately $168,244,440. This represents a 13.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 2,061,235 shares of company stock valued at $436,356,102. 2.90% of the stock is currently owned by corporate insiders.

Illumina Company Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.